What is known and objective: Proton pump inhibitor (PPI) prescribing may often be inappropriate and expose patients to a risk of adverse effects, while incurring unnecessary healthcare expenditure. Our objective was to determine PPI usage in Australia since 2002 and review international studies investigating inappropriate PPI prescribing, including those that discussed interventions to address this issue.
| WHAT IS KNOWN AND OBJECTIVE
Proton pump inhibitors (PPIs) are potent suppressors of acid secretion that are used to treat multiple conditions relating to the gastrointestinal tract. Omeprazole was the first PPI approved in the USA and the United Kingdom in 1989, and then in Australia in 1990, where it has been available with subsidization on the Pharmaceutical Benefits Scheme (PBS) since 1994. [1] [2] [3] Subsequently, esomeprazole, lansoprazole, pantoprazole and rabeprazole became available worldwide.
Soon after PPIs were released, there were concerns about the potential for them to mask symptoms of gastric carcinoma. 4 These concerns have largely disappeared and PPIs are generally considered low-risk medicines, particularly for short-term use; in some countries, they can be obtained without a prescription. 1, 5 Despite the widespread perception of the safety of PPIs, adverse effects have been reported.
Observational studies show that PPI therapy is associated with a 2-to 3-fold increase in Clostridium difficile infection in both community and hospital settings, and an increased risk of infection recurrence.
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There are multiple studies, which demonstrate that cirrhotic patients have an increased risk of acquiring infections while being treated with PPIs. [12] [13] [14] [15] [16] [17] [18] [19] Acute interstitial nephritis is also associated with PPI use. 20, 21 PPIs can prevent clopidogrel being converted to its active metabolite by inhibiting cytochrome P450 2C19, 22 although the clinical significance of this interaction is uncertain. [22] [23] [24] [25] [26] [27] [28] If prescribing a PPI in combination with clopidogrel, pantoprazole or lansoprazole may be preferred as these PPIs are less potent CYP2C19 inhibitors. 
| METHODS
We conducted a narrative literature review on inappropriate PPI use. Firstly, we identified through MEDLINE and Google Scholar any published literature until the end of 2016 (n = 116) citing our aforementioned paper 40 from 2000. The abstract of these papers were read, and 51 were considered relevant to this literature review. Studies were included if they were focused on the overuse or improper use of PPIs, including studies which took place within specific patient groups.
Studies were excluded if they sought to determine a link between PPI use and adverse effects, if they investigated histamine-2 antagonists, or were not written in English.
In addition, to identify studies investigating the inappropriate use of PPIs, MEDLINE and Google Scholar searches until the end of 2016 were conducted using the following combination of MESH terms: "Proton pump inhibitor," "PPI," "omeprazole," "pantoprazole,"
"rabeprazole," "lansoprazole," "esomeprazole," "overuse," "inappropriate," "misuse," "acid suppressant," "intervention." Only papers available in English, and using human data, were included. These search terms 
| RESULTS AND DISCUSSION

| Evidence and extent of inappropriate use
In Australia, the use of PPIs increased since 2002 without a corresponding increase in the prevalence of gastro-oesophageal reflux disease (GORD). Table 1 .
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The studies were conducted in various settings, with the majority as frequent reviews, due to the potential risk-benefit ratio of these medicines.
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| Reasons for inappropriate prescribing
Prescriber and patient factors lead to inappropriate prescribing of PPIs. Prescribers may prescribe a PPI inappropriately because they perceive that PPIs are harmless medicines, perhaps leading to overprescribing and less rigorous follow-up. [83] [84] [85] Nearly all the adverse outcomes associated with PPIs occur among patients who receive long-term therapy; minimizing the duration of treatment by periodically reviewing a patient's need for ongoing therapy could eliminate or substantially reduce the risk of adverse outcomes. 27, 28 In cases where PPIs have been initiated in hospital with an expectation that therapy will be reviewed in the community, some general practitioners (GPs) may be reluctant to review because they value the competence of the initiating hospital physicians and the GPs may lack knowledge of the current evidence-based guidelines. 
| Interventions to improve appropriate PPI use
Effective interventions have included a population-wide education and promotion strategy, academic detailing for GPs, and hospital inpatient deprescribing. 86 A number of international studies have trialled educational programmes. One implemented a simple education programme to encourage doctors to discontinue inappropriate, pre-existing PPI therapy. The rate of inappropriate prescribing only decreased slightly from 54% to 51%, and the intervention was not considered successful. 44 A targeted education programme resulted in interventions for inappropriate prescribing rising from 9% to 46% of patients taking PPIs. 55 The researchers implemented a 4-week educational strategy in a hospital in Scotland, which involved providing information to medical staff about the recommendations for prescribing PPIs, and placing large stickers on the charts of patients who were on PPIs. Additionally, posters were placed on wards, weekly emails were sent, and presentations were given highlighting the role of PPIs and when their use was appropriate. McDonald et al 64 used a web-based quality improvement tool in conjunction with education sessions and found that inappropriately prescribed PPIs discontinued at discharge increased from 7.7% per month to 18.5% per month post-intervention.
An Australian trial identified high-dose prescriptions of esomeprazole or pantoprazole using a computerized clinical decision support prompt in the dispensing software of community pharmacies. 87 The prompt encouraged the community pharmacist to approach appropriate patients about PPI dose reduction in consultation with their GP.
The pharmacist was also provided with links to evidence-based educational materials about PPI use for patients and GPs. An anonymous patient survey followed up the PPI intervention group to determine whether the patient had contacted their GP and whether their PPI therapy had been altered. The authors concluded that a simple electronic prompt in dispensing software resulted in a ten-fold increase of pharmacist intervention compared to the control group, produced cost savings and improved the quality of prescribing of PPIs. 
T A B L E 1 Studies examining proton pump inhibitor (PPI) use
| Factors contributing to PPI discontinuation
In addition to the above-trialled interventions, the literature identified additional factors, which may be helpful for the cessation of inappropriate PPI use. The importance of GP review for deprescribing was highlighted by Glinn et al, 92 who determined that GPs recorded better documentation of patients' medication compared to hospital doctors. It has also been suggested that hospital prescribing of PPIs is sometimes introduced where it would be considered inappropriate in general practice prescribing. 93 Additionally, Krag et al 94 found that almost half the patients in their study who had their acid-suppressive therapy discontinued in hospital recommenced therapy on discharge.
This emphasizes the important role a GP could play following a hospital admission. In terms of appropriate hospital prescribing, teaching hospitals were found to be more compliant than non-academic hospitals (50% vs 29% appropriate). 50 GPs with an increased knowledge of PPIs and an understanding of the potential for adverse effects are also more likely to prescribe PPIs for appropriate indications.
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Following up with patients and continuing to recommend step-down therapy were also found to be successful. Deprescribing guidelines, however, may only have short-lived effects on reducing inappropriate PPI prescribing. 96 It has also been suggested that adequate PPI step-down guidelines are already in place, but that the problem lies in ensuring they are properly implemented and utilized in practice, when 60% of long-term (>1 year) PPI users do not attempt to discontinue or step down. 97 Finding ways to encourage this may result in greater alignment between recommendations and actual use of PPIs. 98 Haastrup et al conducted a systematic review on discontinuation strategies and identified tapering doses as the most successful method for encouraging ultimate PPI cessation, although the time period for reducing doses of PPIs remained an unanswered question. 11, 99 Timely electronic reminder messages for GPs during the patient encounter may encourage deprescribing of PPIs. 
| Limitations
The studies contained in this review, from various countries and settings, did not have the same definitions of "appropriate use" for PPIs.
This was generally defined considering indications with clinical evidence, or indications licensed by the manufacturer. A further limitation is that this review was a narrative review and not a systematic review and that it only included English language studies. As such, there are potentially studies in the literature with results that could affect the conclusions drawn from this review.
Calculating the percentage of PPI prescriptions as a percentage of total PBS dispensings is advantageous compared to looking at an increase in raw numbers, as it more accurately reflects the increase with respect to population growth. A limitation of the PBS data is that it does not take into account private prescription or non-prescription use of PPIs.
| WHAT IS NEW AND CONCLUSION
Although the percentages of PPI misuse varied across studies, in all cases it was found that PPIs are being overprescribed both in hospital and community settings. This may make patients more susceptible to a range of adverse effects. 27, 28, 39 Interventions that have shown promise include regular medication reviews, facilitated by electronic prompts, and ongoing education of both health professionals and consumers. 
